Cargando…
Personalized and long-term electronic informed consent in clinical research: stakeholder views
BACKGROUND: The landscape of clinical research has evolved over the past decade. With technological advances, the practice of using electronic informed consent (eIC) has emerged. However, a number of challenges hinder the successful and widespread deployment of eIC in clinical research. Therefore, w...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325412/ https://www.ncbi.nlm.nih.gov/pubmed/34332572 http://dx.doi.org/10.1186/s12910-021-00675-7 |
_version_ | 1783731554883731456 |
---|---|
author | De Sutter, Evelien Borry, Pascal Geerts, David Huys, Isabelle |
author_facet | De Sutter, Evelien Borry, Pascal Geerts, David Huys, Isabelle |
author_sort | De Sutter, Evelien |
collection | PubMed |
description | BACKGROUND: The landscape of clinical research has evolved over the past decade. With technological advances, the practice of using electronic informed consent (eIC) has emerged. However, a number of challenges hinder the successful and widespread deployment of eIC in clinical research. Therefore, we aimed to investigate the views of various stakeholders on the potential advantages and challenges of eIC. METHODS: Semi-structured interviews were conducted with 39 participants from 5 stakeholder groups from across 11 European countries. The stakeholder groups included physicians, patient organization representatives, regulator representatives, ethics committee members, and pharmaceutical industry representatives, and all were involved in clinical research. Interviews were analyzed using the framework method. RESULTS: Interviewees identified that a powerful feature of eIC is its personalized approach as it may increase participant empowerment. However, they identified several ethical and practical challenges, such as ensuring research participants are not overloaded with information and offering the same options to research participants who would prefer a paper-based informed consent rather than eIC. According to the interviewees, eIC has the potential to establish efficient long-term interactions between the research participants and the research team in order to keep the participants informed during and after the study. Interviewees emphasized that a personal interaction with the research team is of utmost importance and this cannot be replaced by an electronic platform. In addition, interviewees across the stakeholder groups supported the idea of having a harmonized eIC approach across the European Member States. CONCLUSIONS: Interviewees reported a range of design and implementation challenges which needs to be overcome to foster innovation in informing research participants and obtaining their consent electronically. It was considered important that the implementation of eIC runs alongside the face-to-face contact between research participants and the research team. Moreover, interviewees expect that eIC could offer the opportunity to enable a personalized approach and to strengthen continuous communication over time. If successfully implemented, eIC may facilitate the engagement of research participants in clinical research. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12910-021-00675-7. |
format | Online Article Text |
id | pubmed-8325412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-83254122021-08-02 Personalized and long-term electronic informed consent in clinical research: stakeholder views De Sutter, Evelien Borry, Pascal Geerts, David Huys, Isabelle BMC Med Ethics Research BACKGROUND: The landscape of clinical research has evolved over the past decade. With technological advances, the practice of using electronic informed consent (eIC) has emerged. However, a number of challenges hinder the successful and widespread deployment of eIC in clinical research. Therefore, we aimed to investigate the views of various stakeholders on the potential advantages and challenges of eIC. METHODS: Semi-structured interviews were conducted with 39 participants from 5 stakeholder groups from across 11 European countries. The stakeholder groups included physicians, patient organization representatives, regulator representatives, ethics committee members, and pharmaceutical industry representatives, and all were involved in clinical research. Interviews were analyzed using the framework method. RESULTS: Interviewees identified that a powerful feature of eIC is its personalized approach as it may increase participant empowerment. However, they identified several ethical and practical challenges, such as ensuring research participants are not overloaded with information and offering the same options to research participants who would prefer a paper-based informed consent rather than eIC. According to the interviewees, eIC has the potential to establish efficient long-term interactions between the research participants and the research team in order to keep the participants informed during and after the study. Interviewees emphasized that a personal interaction with the research team is of utmost importance and this cannot be replaced by an electronic platform. In addition, interviewees across the stakeholder groups supported the idea of having a harmonized eIC approach across the European Member States. CONCLUSIONS: Interviewees reported a range of design and implementation challenges which needs to be overcome to foster innovation in informing research participants and obtaining their consent electronically. It was considered important that the implementation of eIC runs alongside the face-to-face contact between research participants and the research team. Moreover, interviewees expect that eIC could offer the opportunity to enable a personalized approach and to strengthen continuous communication over time. If successfully implemented, eIC may facilitate the engagement of research participants in clinical research. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12910-021-00675-7. BioMed Central 2021-07-31 /pmc/articles/PMC8325412/ /pubmed/34332572 http://dx.doi.org/10.1186/s12910-021-00675-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research De Sutter, Evelien Borry, Pascal Geerts, David Huys, Isabelle Personalized and long-term electronic informed consent in clinical research: stakeholder views |
title | Personalized and long-term electronic informed consent in clinical research: stakeholder views |
title_full | Personalized and long-term electronic informed consent in clinical research: stakeholder views |
title_fullStr | Personalized and long-term electronic informed consent in clinical research: stakeholder views |
title_full_unstemmed | Personalized and long-term electronic informed consent in clinical research: stakeholder views |
title_short | Personalized and long-term electronic informed consent in clinical research: stakeholder views |
title_sort | personalized and long-term electronic informed consent in clinical research: stakeholder views |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325412/ https://www.ncbi.nlm.nih.gov/pubmed/34332572 http://dx.doi.org/10.1186/s12910-021-00675-7 |
work_keys_str_mv | AT desutterevelien personalizedandlongtermelectronicinformedconsentinclinicalresearchstakeholderviews AT borrypascal personalizedandlongtermelectronicinformedconsentinclinicalresearchstakeholderviews AT geertsdavid personalizedandlongtermelectronicinformedconsentinclinicalresearchstakeholderviews AT huysisabelle personalizedandlongtermelectronicinformedconsentinclinicalresearchstakeholderviews |